Abstract:The neurotoxicity associated to the anticancer treatments has received a growing body of interest in the recent years. The development of innovating therapies over the last 20years has led to the emergence of new toxicities. Their diagnosis and management can be challenging in the clinical practice and further research is warranted to improve the understanding of their pathogenic mechanisms. Conventional treatments as radiation therapy and chemotherapy are associated to well-known and under exploration emerging central nervous system (CNS) and peripheral nervous system (PNS) toxicities. The identification of the risk factors and a better understanding of their pathogeny through a "bench to bedside and back again" approach, are the first steps towards the development of toxicity mitigation strategies. New imaging techniques and biological explorations are invaluable for their diagnosis. Immunotherapies have changed the cancer treatment paradigm from tumor cell centered to immune modulation towards an efficient anticancer immune response. The use of the immune checkpoints inhibitors (ICI) and CAR-T cells (chimeric antigen receptor) lead to an increase in the incidence of immune-mediated toxicities and new challenges in the neurological patient's management. The neurological ICI related adverse events (n-irAE) are rare but potentially severe and may present with both CNS and PNS involvement. The most frequent and well characterized, from a clinical and biological standpoint, are the PNS phenotypes: myositis and polyradiculoneuropathy, but the knowledge on CNS phenotypes and their treatments is expanding. The n-irAE management requires a good balance between dampening the autoimmune toxicity without impairing the anticancer immunity. The adoptive cell therapies as CAR-T cells, a promising anticancer strategy, trigger cellular activation and massive production of proinflammatory cytokines inducing frequent and sometime severe toxicity known as cytokine release syndrome and immune effector cell-associated neurologic syndrome. Their management requires a close partnership between oncologist-hematologists, neurologists, and intensivists. The oncological patient's management requires a multidisciplinary clinical team (oncologist, neurologist and paramedical) as well as a research team leading towards a better understanding and a better management of the neurological toxicities.

Neurological imaging of brain damages after radiotherapy and/or chimiotherapy

Neurological complications of modern radiotherapy for head and neck cancer

Mechanisms of radiation-induced brain toxicity and implications for future clinical trials

MRI characteristics of chemotherapy-related central neurotoxicity: a pictorial review

Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents

Neurological complications in oncology and their monitoring and management in clinical practice: a narrative review

Molecular, Cellular and Functional Effects of Radiation-Induced Brain Injury: A Review

A comprehensive preclinical assessment of late-term imaging markers of radiation-induced brain injury

Neurologic Complications of Therapy

Initial Investigation into Microbleeds and White Matter Signal Changes following Radiotherapy for Low-Grade and Benign Brain Tumors Using Ultra-High-Field MRI Techniques

Neurocognitive function after radiotherapy for paediatric brain tumours

Exploring Neuroprotection against Radiation-Induced Brain Injury: A Review of Key Compounds

Introduction to novel developments in radio-imaging and radiotherapy

Neuroimaging Advances in Chemotherapy-Related Cognitive Impairment: from Clinical to Preclinical Research

Susceptibility-weighted magnetic resonance imaging of cerebrovascular sequelae after radiotherapy for pediatric brain tumors

Neuroprotection in radiotherapy of brain metastases: A pattern-of-care analysis in Germany, Austria and Switzerland by the German Society for radiation Oncology - working group Neuro-Radio-Oncology (DEGRO AG-NRO)

Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.

Diagnosis and management of brain radiation necrosis

Mitigating radiation-induced cognitive toxicity in brain metastases: More questions than answers

Neurocognitive considerations in the treatment of meningioma with radiation therapy: applications for quantitative neuroimaging and precision radiation medicine

Neurotoxicity-sparing radiotherapy for brain metastases in breast cancer: a narrative review